Abstract: The invention relates to the compound 2-6-xylidide of quinuclidine-3-carboxylic acid and its pharmaceutically acceptable salts, such as the hydrochloride, which have been found to be effective antiarrhythmic agents. The invention further relates to the production of this antiarrhythmic compound which method is applicable also to the production of related compounds which, however, do not have antiarrhythmic action, e.g. the quinuclidine-2-carboxylic acid xylidides. The compounds are produced according to this method by reacting the quinuclidine carboxylic acid in anhydrous chloroform and oxalyl chloride with the dimethylaniline. The desired compound is produced in high yield with a high degree of purity.

Abstract: Compounds of the general formula ##STR1## wherein X is selected from the group consisting of oxygen CH.sub.2 and CH radicals, and when X designates oxygen, R designates alkyl, isoalkyl, aralkyl, and substituted aryl groups and when X designates ##STR2## then R designates alkyl, phenyl or substituted phenyl group, and A--B is a single bond and when X designates >CH, and A--B is a double bond, R designates alkyl, phenyl or substituted phenyl groups and physiologically acceptable salts of these, and pharmaceutical compositions containing same as active ingredient.

Abstract: Choline salicylate is stabilized in solid form by means of a metal salicylate having a valence of at least 2, preferably aluminum, bismuth, calcium or magnesium salicylate. The composition is stabilized to a still greater degree by the addition thereto of carboxy-methyl cellulose. A still greater degree of stabilization is achieved by forming a complex of the choline salicylate, metal salicylate and carboxy-methyl cellulose. The complex is formed by preparing a solution of the carboxy-methyl cellulose, choline salicylate and metal salicylate, permitting complexng reaction to take place and drying. All of these stabilized forms of choline salicylate are used in solid dosage forms such as granules, tablets, capsules and supporitories for administration to animals and humans, in the course of choline salicylate therapy, to elevate the blood levels of salicylate ion.